CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. The company is headquartered in Houston, Texas and currently employs 4 full-time employees. The company went IPO on 2019-11-08. The firm's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The firm's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.
Follow-Up Questions
Who is the CEO of CNS Pharmaceuticals Inc?
Mr. John Climaco is the Chief Executive Officer of CNS Pharmaceuticals Inc, joining the firm since 2017.
What is the price performance of CNSP stock?
The current price of CNSP is $6.75, it has decreased 0% in the last trading day.
What are the primary business themes or industries for CNS Pharmaceuticals Inc?
CNS Pharmaceuticals Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is CNS Pharmaceuticals Inc market cap?
CNS Pharmaceuticals Inc's current market cap is $3.8M
Is CNS Pharmaceuticals Inc a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for CNS Pharmaceuticals Inc, including 2 strong buy, 4 buy, 2 hold, 0 sell, and 2 strong sell
